Drugs facing NCE-1 in 2027

1. List of Aemcolo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741948 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(2 years from now)

US8529945 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(2 years from now)

US8486446 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(2 years from now)

US8263120 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(2 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 16, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: November, 2027

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

2. List of Nuzyra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2023

(3 months from now)

US7326696 PARATEK PHARMS INC Amino-methyl substituted tetracycline compounds
Sep, 2023

(7 months from now)

US8383610 PARATEK PHARMS INC Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Sep, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265740 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(6 years from now)

US10124014 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(6 years from now)

US9724358 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(6 years from now)

US9314475 PARATEK PHARMS INC Oral and injectable formulations of tetracycline compounds
Mar, 2031

(8 years from now)

US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof
Aug, 2037

(14 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections; Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Xerava drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10961190 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796245 TETRAPHASE PHARMS C7-fluoro substituted tetracycline compounds
Aug, 2029

(6 years from now)

US8906887 TETRAPHASE PHARMS C7-fluoro substituted tetracycline compounds
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2023
Generating Antibiotic Incentives Now (GAIN) Aug 27, 2028

Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient

NCE-1 date: August, 2027

Market Authorisation Date: 27 August, 2018

Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

4. List of Zemdri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9688711 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

US8383596 CIPLA USA Antibacterial aminoglycoside analogs
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822424 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

US9266919 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 25, 2023
Generating Antibiotic Incentives Now (GAIN) Jun 25, 2028

Drugs and Companies using PLAZOMICIN SULFATE ingredient

NCE-1 date: June, 2027

Market Authorisation Date: 25 June, 2018

Treatment: Method of using plazomicin to treat bacterial infections

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in